ClinicalTrials.gg
Enrolling by invitationNCT04430426Updated Aug 31, 2026

Heterozygous Individuals for AGXT and Kidney Stones

An interventional study of Controlled Diet in Kidney Stone and Urolithiasis, Calcium Oxalate, sponsored by University of Alabama at Birmingham. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Kidney Calculi by University of Alabama at Birmingham — 6 open to participants now, 12 under way, none of them phase 3. Kidney Calculi · University of Alabama at Birmingham.

Planned enrollment
16th of 17
4 · median 40
Started
2027
the only one that year
No phase
17 of 17
6 open now
Primary completion
2031-08
later than 11 of 11 live
Registered
7th of 17
by date

Among the 17 studies in Kidney Calculi by University of Alabama at Birmingham, this one is the 16th largest by planned enrollment, is the only one that started in 2027, is one of 17 with no phase, reaches primary completion later than 11 of the 11 other live ones, and was the 7th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

6 of the 17 studies in Kidney Calculi by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Kidney Calculi by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

This study seeks to examine the effects of a heterozygous mutation of the AGXT gene in a stone forming population on endogenous oxalate production. Participants will consume a controlled low-oxalate diet and provide blood and urine samples to measure the amount of oxalate in their bodies.

03

Conditions studied

  • Kidney Stone
  • Urolithiasis, Calcium Oxalate

Browse trials for

Keywords

  • kidney stone
  • oxalate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 18 years of age
  • history of calcium oxalate stones
  • heterozygous mutation of the AGXT gene, as evidenced by results from the Invitae Nephrolithiasis Panel
  • willingness to comply with a controlled diet for five days

Exclusion criteria

Exclusion Criteria:

  • pregnant individuals
  • individuals who are currently breast feeding
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    Controlled Dietary Study

    Participants will consume the controlled diet for five days. Participants will provide urine and blood samples to measure oxalate levels.

    Other: Controlled Diet

Interventions

  • OtherControlled Diet

    Participants will consume a controlled low oxalate diet for five days.

06

What researchers measure

Primary outcomes

  1. Urinary Oxalate Excretion

    Urinary oxalate excretion from urine samples will be measured as mg/day

    Time frame: Baseline through Day 4

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2027; primary completion for Aug 2031, 49 months later.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 49 months is above that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2020
First posted
Jun 12, 2020
StartEst.
Jul 1, 2027
Primary completionEst.
Aug 1, 2031
CompletionEst.
Aug 1, 2032
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04430426
Responsible party
Kyle D. Wood (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Jun 12, 2020
Start date
Jul 1, 2027 (estimated)
Primary completion
Aug 1, 2031 (estimated)
Completion
Aug 1, 2032 (estimated)
Last update
Aug 31, 2026

Study contacts

Kyle Wood, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion